The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).
 
Louise Emmett
Consulting or Advisory Role - Advancell; Astellas Pharma; Clarity Pharmaceuticals; Novartis
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; mundipharma; Novartis
Research Funding - Clarity Pharma (Inst); Novartis (Inst); PCF (Inst)
Travel, Accommodations, Expenses - Advancell
 
Shalini Subramaniam
Research Funding - AAA/Endocyte/Novartis (Inst); Astellas Pharma (Inst)
Travel, Accommodations, Expenses - MSD
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Andrew Nguyen
Consulting or Advisory Role - Novartis
 
Anthony Joshua
Stock and Other Ownership Interests - Opthea; Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
Andrew Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Pfizer; Telix Pharmaceuticals
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Merck Sharp & Dohme
 
Sze Ting Lee
No Relationships to Disclose
 
Siobhan Ng
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Johnson & Johnson; Pfizer
 
Roslyn Francis
Employment - AIQ Solutions (I)
Stock and Other Ownership Interests - AIQ Solutions (I)
Consulting or Advisory Role - AIQ Solutions (Inst)
Research Funding - AIQ Solutions (Inst)
 
Jeffrey Goh
Stock and Other Ownership Interests - ICON Cancer Care
Honoraria - MSD Oncology
Consulting or Advisory Role - Abbvie; Eisai; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca/MedImmune; Eisai; Janssen; MSD Oncology
Travel, Accommodations, Expenses - Bayer
 
David Pattison
No Relationships to Disclose
 
Thean Tan
No Relationships to Disclose
 
Ian Kirkwood
Stock and Other Ownership Interests - CSL Limited; Sonic Healthcare; Telix Pharmaceuticals
 
Shahneen Sandhu
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Alison Zhang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; MSD Oncology; Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Janssen Oncology; Merck; Merck Sharp & Dohme; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; MSD Oncology
 
Michael Hofman
Consulting or Advisory Role - Janssen; MSD; Novartis (Inst)
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Debiopharm Group (Inst); Novartis
 
Hayley Thomas
No Relationships to Disclose
 
Andrew Martin
No Relationships to Disclose
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose